Fuel your career growth in the dynamic and challenging biobased economy
While Europe and North America recover from recession, emerging markets like Brazil, Russia, India and China (BRIC) are still enjoying double digit growth in most consumer sectors.
Industrial Biotechnology offers an exciting new opportunity to drive real growth, reach new markets, reduce costs and meet sustainability objectives.
Industrial Biotechnology, sometimes known as White Biotechnology, is a key enabling technology in the biobased economy and is already transforming the way chemicals, plastics and other materials are made.
Many leading players in the chemical sector (e.g. BASF, Dupont, Evonik and DSM) as well as a growing number of smaller companies and new ventures are already active in this sector, and many more are joining. As momentum gathers pace it is critical that you have a thorough understanding of the key technologies, the opportunities they represent for your business and how to invest your resource most effectively to capitalise on these new markets.
This 3-day MBA course on Industrial Biotechnology will help you get quickly up to speed on the potential opportunities in this marketplace and help you focus on how your company could benefit from these exciting developments.
TUESDAY 13 March
- Introduction: Industrial Biotechnology and the Biobased Economy
- Applications and markets
WEDNESDAY 14 March
- The supply and value chain
- Research & innovation
- Industrial biotechnology and business development
THURSDAY 15 March
- Policies and regulations in the biobased economy
- Breakout sessions
More about the Expert Instructors:
Dirk Carrez is a Bio-engineer and holds a PhD in Agricultural Sciences. Between 2004 and 2011, he was the Director Industrial Biotechnology at EUROPABIO (The European Association for BioIndustries), where he coordinated the activities in the area of industrial biotechnology and the "biobased economy", as well as horizontal issues, such as research & innovation, SMEs & access to finance, IPR, etc. Since the beginning of 2011, he has been the Associate Consultant at Smithers Apex for industrial biotech related issues, and supports the strategy and business development of BIO BASE EUROPE, one of the first open innovation and education centers for the biobased economy in Europe.
Bruno Ferreira has a strong and broad bioengieering background, and is experienced in diverse areas like microalgae, the optimization microbial processes and the development of culture systems for stem cells. He is the Co-author of over 30 publications and member of several scientific societies.
Martin Austin is a member of the UK Knowledge Transfer Network in Industrial Biotechnology, a representative to the OECD task force on Industrial Biotechnology and an advisor to Europabio which represents the European Commission's interests in Industrial Biotechnology. He was previously a Principal in the Paul Capital Partners Royalty Funds, as well as Head of Business Development for the Pharmaceuticals Division at F. Hoffmann-La Roche. He has recently published "Business Development for the Biotechnology and Pharmaceutical Industry".